During the past decade we have been serving as a trusted resource and advisor to pharmaceutical, medical device, and biotechnology companies. Through our series of life sciences case studies, we outline some of the actionable results that we have produced for our clients. To read a case study concentrating on the below areas, click on the topic of interest. Case Studies Page.
KOL Identification and Profiling
Methodology: We started with a list (including demographics) of 27,000 cardiologists and 1,400 electrophysiologists and augmented the database with data from a wide range of sources relevant to the disease state:
- Investigators of clinical trials
- Authors of journal articles
- Editorial board members of journals
- Association officers
- Administrative positions at hospitals and universities
- Guideline authors
- Speakers at conventions and symposia
- Program planners
- Physicians at top-rated hospitals
- Hospitals conducting high numbers of related procedures
Snowfish leveraged our proprietary software to filter, sort, and integrate millions of data elements.
Results: We derived a manually verified list of the top 500 KOLs in the field. Our link mapping software derived 33,000 relevant links between the KOLs and between the KOLs and other physicians. Using our sophisticated weighting system, we then derived lists of those most suitable for a number of programs for the client’s new drug:
- National speakers
- Regional speakers
- Advisory board members
We also listed the “rising stars” among the KOLs and those KOLs that were considered regional as opposed to national. All results were presented in easy-to-use Excel spreadsheets, with “pull-down” filters to quickly sort or select KOLs based on particular factors (including client sales region). A report of the findings was also presented in PowerPoint format, highlighting all major results.
At the final presentation, our team was personally commended by the client’s VP of marketing, and client staff later remarked on both the comprehensiveness of the results and the ease and power of using the deliverables.
Strategic Product Development
Methodology: Snowfish developed an overall product evaluation matrix. Each product analysis involved several months of work with very detailed analysis. We leveraged multiple primary and secondary data sources including:
- Physician interviews
- Procedure and diagnostic data
- Stock analyst reports
- Clinical trial results
- Association data
- Corporate websites
- Press releases
- NIH data
- Annual reports
- SEC filings
- AMA data
Results: Snowfish was able to develop a very clear and compelling analytic framework for the company to compare multiple product opportunities in vastly different therapeutic areas. We were able to evaluate each product concept along the following business and clinical concepts:
- Physician interest
- Product differentiation
- Patient interest
- Product revenue
- Market profitability
- Entry barriers
- Market growth
- Distribution/physician population
- Competitive intensity
- Rate of adoption
- Untreated patient population
Snowfish also assigned a relative weighting to each variable that was client driven. Based on the relative weightings, the client was able to get a very clear picture of the market opportunity. This has enabled the company to focus their development efforts and avoid wasting millions of dollars on product concepts that were very unlikely to ever pay off. Snowfish continues to work with the client on multiple projects.
|External Factor||Product A||Product B||Product C||Product D||Product E|
|Rate of Adoption||9||7||2||1||3|
Product Development Research
The management team had been told by their board members and KOLs that the product had enormous potential. Snowfish was asked to confirm the assumptions and make a recommendation as to whether the market opportunity merited investment.
Methodology: In order to quickly assess the market, Snowfish thought there were two critical elements. The first element was to gain a physician perspective at leading teaching institutions not affiliated with the company to understand the number of physicians that were experienced with the surgical approach. The second element was to see if the procedure volume mirrored the board’s assumptions.
Snowfish identified and recruited half a dozen physicians from leading teaching institutions across the United States. We also analyzed procedure volumes based on CPT codes.
Results: It quickly became apparent that there was a strong match between what we were hearing from non company affiliated physicians and the CPT codes. In fact, both data elements were in complete agreement. They both indicated that there was not a market for the medical simulation product. Based on these two strong data points, Snowfish recommended that the company should not pursue the product development.
Below are some of the product development research results from physician surveys at leading institutions:
|Total Interventional Cardiologists||16||5||7||16||13|
|Interventional Cardiologist Trained on Procedure||1||1||2||4||2|
|Product A||Study A initiates||Data from Study B
presented at Association meeting
|Study C to release interim results|
|Product B||New indication
|Study R expected completed|
|Product C||Results from
|Study Y should be completed||Interim results of
|Product D||Study Z results to
be presented at Association meeting
|Interim results of
|Study O initiates|
|Product E||Study V initiates||Data from Study N
presented at Association meeting
|Interim results of
|Study M expected completed|
|Product A||New indication for PCI (end of XXX?). Promote efficacy of XXX regimen in both UA/NSTEMI and STEMI patients undergoing PCI. Leverage data from XXX along with other data in STEMI including XXX and studies by XXX et al.|
|Product B||May be pushing to continue to capture patients eligible for early administration of eptifibatide. May position as optimal GP IIb/IIIa inhibitor to be used with early invasive strategy.|
|Product C||Continue efforts to expand use upstream in AMI patients planned for angioplasty.|
|Product D||Depending upon what XXX shows, focus may be on either replacing heparin or GP IIb/IIIa inhibitors in upstream management of UA/NSTEMI patients. Focus of strategy and indication will depend upon the results.|
|Product E||May leverage XXX to support role of high-dose clopidogrel in a new standard of care, however may still promote benefit of the high-dose without the need for the addition of a GP IIb/IIIa inhibitor.|
Strategic Partnering Case Study
Methodology: Snowfish started out with a list of approximately 7500 organizations which was to be narrowed down through various factor weightings and re-ranking based upon a profile developed by both Snowfish and our client depicting the ideal partner organization. This analysis involved several months of work with very detailed analysis involving clinical, business, and technical expertise. The multiple disease-state-specific factors that we analyzed included:
- Articles published by investigators at organization
- Guidelines published by investigators at organization
- Clinical trials conducted at the organization (and how many were sponsors vs. locations)
- NIH grants awarded to organization
- If the organization had relevant fellowship program
- Current relationships between the company and investigators within the organization
- Community involvement
- Various measures of alignment
Once we were able to identify our “short-list”, we conducted one-on-one in-depth interviews with key individuals within the organizations to detail their profile and offer our client everything they needed to know so that they could have a very fruitful initial meeting.
Results: Snowfish was able to narrow a tremendous number of organizations to the top 30 or the top 99.6% percentile. Very specific details about their organization including staff, research, goals, interests and aspirations were provided in a user-friendly format. Our client now has everything they need for senior management to make informed decisions on which organizations with whom to take the first step and how best to maximize the efficiencies of their initial meeting.